MDT

99.7

-0.07%↓

145.92

+0.05%↑

VEEV

238.84

+1.15%↑

HQY

97.7

+3.12%↑

PHR.US

17.49

+1.22%↑

MDT

99.7

-0.07%↓

145.92

+0.05%↑

VEEV

238.84

+1.15%↑

HQY

97.7

+3.12%↑

PHR.US

17.49

+1.22%↑

MDT

99.7

-0.07%↓

145.92

+0.05%↑

VEEV

238.84

+1.15%↑

HQY

97.7

+3.12%↑

PHR.US

17.49

+1.22%↑

MDT

99.7

-0.07%↓

145.92

+0.05%↑

VEEV

238.84

+1.15%↑

HQY

97.7

+3.12%↑

PHR.US

17.49

+1.22%↑

MDT

99.7

-0.07%↓

145.92

+0.05%↑

VEEV

238.84

+1.15%↑

HQY

97.7

+3.12%↑

PHR.US

17.49

+1.22%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

20.82 3.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.99

Максимум

21.16

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+92.28% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	628M 1.8B
Предишно отваряне	17.08
Предишно затваряне	20.82

Настроения в новините

By Acuity

75%

25%

351 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.01.2026 г., 21:14 ч. UTC

Значими двигатели на пазара

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6.01.2026 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6.01.2026 г., 17:41 ч. UTC

Значими двигатели на пазара

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6.01.2026 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Advent International Leads InPost Takeover Offer, Sky News Says

6.01.2026 г., 15:37 ч. UTC

Значими двигатели на пазара

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

6.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6.01.2026 г., 23:19 ч. UTC

Пазарно говорене

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6.01.2026 г., 22:53 ч. UTC

Пазарно говорене

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.01.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6.01.2026 г., 20:59 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced Imminently, Sources Say -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6.01.2026 г., 20:01 ч. UTC

Пазарно говорене

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6.01.2026 г., 19:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6.01.2026 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6.01.2026 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4B Hg Acquisition

6.01.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

6.01.2026 г., 15:57 ч. UTC

Пазарно говорене

Crude Futures Ease Back From Early Gains -- Market Talk

6.01.2026 г., 15:34 ч. UTC

Пазарно говорене

Печалби

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6.01.2026 г., 15:27 ч. UTC

Пазарно говорене

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

92.28% нагоре

12-месечна прогноза

Среден 39.11 USD 92.28%

Висок 56 USD

Нисък 27 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

351 / 373 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.